Search results
Showing 136 to 150 of 163 results for copd
Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)
This evidence summary has been updated and replaced by NICE guideline 115.
Mental health of adults in contact with the criminal justice system (NG66)
This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.
View recommendations for NG66Show all sections
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (CG101)
This guideline has been updated and replaced by NICE guideline NG115.
Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)
This evidence summary has been updated and replaced by NICE guideline 115.
Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)
This evidence summary has been updated and replaced by NICE guideline 115.
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
This evidence summary has been updated and replaced by NICE guideline 115.
This evidence summary has been updated and replaced by NICE guideline 115.
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
This quality standard covers prevention of falls and assessment after a fall in older people (aged 65 and over) who are living in the community or staying in hospital. It describes high-quality care in priority areas for improvement.
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Identifying people at risk of falling
- Quality statement 2: Multifactorial risk assessment for older people at risk of falling
- Quality statement 3: Multifactorial intervention
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .